XML 26 R6.htm IDEA: XBRL DOCUMENT

Description of the Business	9 Months Ended
Description of the Business	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business Immune Design Corp. (we, us or our) is a clinical-stage immunotherapy company focused on cancer with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. We have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. We are developing multiple product candidates from our two discovery platforms, ZVex™ and GLAAS™. Our primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase 1 trials, as well as a randomized Phase 2 trial studying CMB305 plus atezolizumab compared to atezolizumab alone. CMB305 is a prime-boost approach, in which LV305 from our ZVex platform is dosed sequentially with G305 from our GLAAS platform. Although we are focusing our development efforts on CMB305 and G100, we have an ongoing expansion trial of LV305 alone at the highest dose studied in its dose-escalation Phase 1 trial. We were incorporated in February 2008 in the State of Delaware. Our operations are headquartered in Seattle, Washington, and we have an additional facility in South San Francisco, California.